CN1634085A - Injectio of aspirin and dipyridamole and its preparing process - Google Patents
Injectio of aspirin and dipyridamole and its preparing process Download PDFInfo
- Publication number
- CN1634085A CN1634085A CN 200410087649 CN200410087649A CN1634085A CN 1634085 A CN1634085 A CN 1634085A CN 200410087649 CN200410087649 CN 200410087649 CN 200410087649 A CN200410087649 A CN 200410087649A CN 1634085 A CN1634085 A CN 1634085A
- Authority
- CN
- China
- Prior art keywords
- injection
- dipyridamole
- aspirin
- grams
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides an injection of aspirin and dipyridamole and its preparing process, which comprises aspirin and dipyridamole by the proportion of aspirin : dipyridamole = 1-99 : 99-1, the injection can be made into the forms of injection, freeze-dried powder injection, germ-free powder injection, and high capacity fluid infusion. The preparation can be applied for treating cardiovascular and cerebrovascular diseases.
Description
Technical field:
The present invention relates to aspirin-dipyridomole compound injection and preparation method thereof, belong to the technical field of medicine and preparation method thereof.
Background technology:
Antiplatelet aggregation is the important step of cardiovascular and cerebrovascular diseases.Aspirin is the medicine of first generation antiplatelet aggregation, and it can stop thrombosis, is used to prevent temporal cerebral ischemia seizure, myocardial infarction, atrial fibrillation, unstable angina pectoris etc.Dipyridamole also has antithrombotic effect.It can suppress hematoblastic first and assemble mutually and second gathering mutually.Can suppress hematoblastic release reaction during high concentration.Two medicines are usually used in thrombotic disease and ischemic heart desease.The newest fruits of modern medicine study is emphasized this thought: unite the medicine of the antiplatelet aggregation that uses different mechanism of action, help to prevent cerebral infarction.You Bannuo of neuropathy section of hospital of Switzerland Vaudois University Centre (Luis A.urbano) and ripple Gus Laski (Julien Bogousslavsky) are checked finishing with ongoing research about therapeutic alliance: the European stroke prevention research of newly finishing 2 shows, unite and use aspirin to compare with the former with single, reduced by 22% danger with persantin (dipyridamole).Therefore, the author sums up, " the anti-platelet medicine of uniting different mechanism of action is a kind of attractive methods ".There are many researchs all this being assessed at present.[" cerebrovascular disease " goes up " antiplatelet drug is used to prevent cerebral infarction: from the single therapy to the therapeutic alliance " literary composition] (Cerebrovasc Dis 2004; 17 Suppl 1:74-80).
The solid preparation of aspirin phenacetin caffeine dipyridamole, in recent years, existing clinically the application.World health organisation recommendations is the antithrombotic choice drug; U.S. antiplatelet experimenter association, famous PARISI experimental verification is an optimal drug of preventing and treating myocardial infarction.But its injection type is seen any report is not arranged.The invention provides injection, freeze-dried powder, the aseptic powder injection of aspirin phenacetin caffeine dipyridamole, the preparation method of Da Rong transfusion.Purpose is to provide a kind of safe, effective, novel new drug that is used for coronary vasodilation and anti-platelet aggregation for clinical.For the illness of removing numerous cardio-cerebral vascular disease patients provides new treatment means.
Summary of the invention:
As mentioned above, the objective of the invention is to fill up the blank of Injectio of aspirin and dipyridamole, provide a kind of new safely and effectively medicine and preparation method thereof for curing cardiovascular and cerebrovascular disease.Formation of the present invention is: the aspirin phenacetin caffeine dipyridamole is by aspirin (C
9H
8O
4) and dipyridamole (C
24H
40N
8O
4), being prepared from through scientific formula, its proportioning is: Ah takes charge of woods: dipyridamole=1-99: 99-1.Its optimum ratio is: Ah takes charge of woods: dipyridamole=75: 25.This injection is liquid and injectable powder.Its dosage form comprises Ah department woods dipyridamole injection liquid, freeze-dried powder, aseptic powder injection and large capacity transfusion.To satisfy different patients' needs, make things convenient for selection of clinical to use.Its preparation technology is: according to given ratio aspirin, dipyridamole are equipped with proper amount of water for injection, subsequent technique is to be made into injection or to make freeze-dried powder, aseptic powder injection by prior art according to prior art.In this injection, excipient can be added, also any excipient can be do not added.Compared with prior art, the present invention constitutes simply, and the quality of production is controlled easily.Be made into injectable powder, make constant product quality, long shelf-life, and drug delivery, carry, easy to use.This product is applicable to coronary vasodilation and antiplatelet aggregation, and the collaborative platelet aggregation effect that reduces is arranged.Be used for the control of thromboembolism, reduce myocardial infarction, the formation of cerebral thrombosis and chronic anginal treatment also can be used for valvular heart disease and artificial valve's operation behind the surgical operation, constitutional, recurrent thrombus phlebitis etc.
Embodiment:
Embodiment 1: it is that dipyridamole 50 grams are formulated by Ah department woods 150 grams.Ah department woods 150 grams, dipyridamole 50 grams are equipped with water for injection 5000ml, are made into injection according to prior art.Said preparation does not add any excipient.
Embodiment 2: it is that dipyridamole 25 grams are formulated by Ah department woods 75 grams.Ah department woods 75 grams, dipyridamole 25 grams are equipped with water for injection 5000ml, are made into injection according to prior art.Said preparation does not add any excipient.
Embodiment 3: it is that dipyridamole 75 grams are formulated by Ah department woods 225 grams.Be equipped with water for injection 250000ml in the manufacturing process, make large capacity transfusion by prior art.
Embodiment 4: it is that dipyridamole 50 grams are formulated by Ah woods 150 grams.With aspirin 150 grams, it is an amount of that dipyridamole 50 grams are equipped with water for injection, is made into lyophilized injectable powder according to prior art.Can be in said preparation with mannitol as excipient.
Embodiment 5: it is that dipyridamole 25 grams are formulated by Ah woods 75 grams.With aspirin 75 grams, it is an amount of that dipyridamole 25 grams are equipped with water for injection, is made into lyophilized injectable powder according to prior art.Can be in said preparation with mannitol as excipient
Embodiment 6: it is that dipyridamole 50 grams are formulated by Ah department woods 150 grams.Be made into aseptic injection according to prior art.
Claims (5)
1, a kind of aspirin phenacetin caffeine dipyridamole injection preparation that is used for antiplatelet aggregation.It is characterized in that: said aspirin phenacetin caffeine dipyridamole injection preparation is formulated by aspirin, dipyridamole, and its proportioning is: aspirin: dipyridamole=1～99: 99～1.
2, according to the described injection of claim 1, it is characterized in that: said injection, its preferred proportioning: aspirin: dipyridamole=75: 25.
3, according to the described injection of claim 1, it is characterized in that: said injection is injection, freeze-dried powder, aseptic powder injection and large capacity transfusion.
4, according to the manufacture method of the described injection of claim 3: it is characterized in that, according to given ratio, aspirin, dipyridamole are equipped with proper amount of water for injection, and subsequent technique is made into injection, freeze-dried powder, aseptic powder injection and large capacity transfusion according to prior art.
5, according to the manufacture method of the described injection of claim 4, it is characterized in that: in manufacturing process, the excipient that can add, solubilizing agent, cosolvent are mannitol and all adjuvants that pharmacy allowed.Also can not add any excipient, solubilizing agent, cosolvent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410087649 CN1634085A (en) | 2004-11-24 | 2004-11-24 | Injectio of aspirin and dipyridamole and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410087649 CN1634085A (en) | 2004-11-24 | 2004-11-24 | Injectio of aspirin and dipyridamole and its preparing process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1634085A true CN1634085A (en) | 2005-07-06 |
Family
ID=34847476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410087649 Pending CN1634085A (en) | 2004-11-24 | 2004-11-24 | Injectio of aspirin and dipyridamole and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1634085A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103108874A (en) * | 2010-05-31 | 2013-05-15 | 基因里克斯(英国)有限公司 | Processes for the preparation of dipyridamole |
-
2004
- 2004-11-24 CN CN 200410087649 patent/CN1634085A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103108874A (en) * | 2010-05-31 | 2013-05-15 | 基因里克斯(英国)有限公司 | Processes for the preparation of dipyridamole |
| CN103108874B (en) * | 2010-05-31 | 2016-11-16 | 基因里克斯(英国)有限公司 | For the method preparing dipyridamole |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2004126950A (en) | USE OF CO-EMITTING COMPOUNDS IN THE PRODUCTION OF A MEDICINE FOR TREATMENT OF INFLAMMATORY DISEASES | |
| JP2014515028A5 (en) | ||
| JP2017002083A5 (en) | ||
| JP2010120964A (en) | Endogenous repair factor production promoter | |
| JP2013529654A (en) | Pharmaceutical composition comprising levocarnitine and dobesylate | |
| US20170128514A1 (en) | Pharmaceutical composition for treating cardio-cerebrovascular diseases and method for preparing the same | |
| CN103906506A (en) | Controlled dosing of clopidogrel with gastric acid inhibition therapies | |
| CN102389436A (en) | Medicinal composition for resisting platelet aggregation | |
| CN1634085A (en) | Injectio of aspirin and dipyridamole and its preparing process | |
| CN104644595B (en) | A kind of solid composite medicament containing clopidogrel | |
| EA200900214A1 (en) | PHARMACEUTICAL COMPOSITION OF RIFABUTIN FOR THE TREATMENT OF TUBERCULOSIS, THE WAY OF ITS OBTAINING AND THE METHOD OF TREATMENT | |
| JP6928611B2 (en) | combination | |
| CN105853378A (en) | Resveratrol trinocotinate nanocrystal quick release capsule preparation and preparation technology thereof | |
| CN115120611A (en) | NO donor micelle composition and preparation method and application thereof | |
| CN1771944A (en) | Application of high-solubility berberine in preparing medicine | |
| CN111374981B (en) | Drug combination of pimozide and methotrexate and its applications | |
| RU2007122038A (en) | METHOD FOR TREATING MYOCARDIAL INFARCTION PATIENTS | |
| US8834932B2 (en) | Anticoagulant-conjugated carbon nanocapsule, antithrombotic agent containing thereof | |
| WO2020143548A1 (en) | Method for preventing, treating or delaying myocardial damage using neuregulin and composition | |
| JPS63501360A (en) | Prostacyclin, its analogs or prostaglandin and thromboxane analogs for the treatment of thrombotic and thromboembolic diseases | |
| CN107582560A (en) | The thrombus dissolving effect and its application of akebiasaponin D | |
| Awan et al. | Treatment of low high-density lipoprotein cholesterol | |
| US20040092592A1 (en) | Stabilized L-Arginine platelet aggregation inhibitory compositions and processes for making same | |
| Svetikienė et al. | Successful treatment of right heart thrombi and acute massive pulmonary embolism by repeated thrombolysis | |
| WO2011052499A1 (en) | Pharmaceutical composition having improved storage stability |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |